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Background: Neutralizing antibodies in breast milk may adversely influence the immune response to live oral
vaccines. Withholding breastfeeding around the time of vaccine administration has been suggested for improving
vaccine performance. However, we do not know whether mothers find withholding breastfeeding around the time
of vaccination acceptable and how they perceive this recommendation.
Methods: In a clinical study designed to examine predictors of poor immune response to rotavirus vaccine in
infants in India, Rotarix® was administered to infants at 6 and 10 weeks with other childhood vaccines. For the
study, 400 mother–infant pairs were randomized into two groups in a 1:1 ratio. Mothers were either recommended
to withhold breastfeeding or were encouraged to breastfeed half an hour before and after administration of
Rotarix®. The mother–infant pairs were observed and the breastfeeding intervals were recorded during this period.
Mothers were administered a questionnaire about their perception of the intervention after the infants received the
second dose of Rotarix®.
Results: Almost 98% (391/400) of the infants received both doses of Rotarix®. Adherence to the recommendations
was high in both groups. All mothers in the group who were asked to withhold breastfeeding did so, except one
who breastfed her infant before the recommended time after the first dose of Rotarix®. Of the mothers, 4% (7/195)
reported that the recommendation to withhold breastfeeding was difficult to follow. All mothers in this group
reported that they would withhold breastfeeding at the time of vaccination if they were asked to by a health-care
provider. Only one mother responded that withholding breastfeeding would be a reason for not giving rotavirus
vaccine to her infant.
Conclusions: Withholding breastfeeding half an hour before and after vaccination appears to be acceptable to
mothers in this setting. If withholding breastfeeding produces an improvement in the performance of the vaccine,
it could be used to increase the public health impact of rotavirus immunization.
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Rotavirus is the most common cause of severe dehydrat-
ing diarrhea worldwide in infants and young children, kill-
ing approximately 453,000 children under the age of 5
each year [1]. Rotavirus is particularly threatening in India,
causing around 100,000 deaths in young children every
year [2]. Vaccination remains a cornerstone in the preven-
tion of rotavirus-associated morbidity and mortality.
The two oral rotavirus vaccines commercially available,
Rotarix® (GlaxoSmithKline Biologicals, Rixensart, Belgium)
and RotaTeq (Merck and Co, PA, USA), have been shown
to be safe and effective [3]. Overall, rotavirus vaccines are
associated with 74% and 61% reductions in very severe
and severe rotavirus infections, respectively, and a 47% re-
duction in rotavirus-related hospital admissions [4-8].
However, in low-income countries, these vaccines have a
lower efficacy compared to other oral vaccines like polio
and cholera [9]. In impoverished high-mortality settings,
host factors, including maternal antibodies, interfering
bacterial and viral agents, and child and maternal mal-
nutrition, may affect immune responses [10].
In vitro studies of the neutralizing effect of breast milk
have suggested that withholding breastfeeding around
the time of rotavirus vaccine administration may impact
vaccine performance [11]. Efficacy trials have reported
no difference between breastfed and non-breastfed in-
fants. However, in these studies the breastfeeding practices
were self-reported and the interval between breastfeeding
and vaccine administration was not adequately evaluated
[10,12,13]. Breast milk from Indian mothers is reported to
have much higher concentrations of rotavirus-neutralizing
antibodies than breast milk from mothers in industrialized
countries [11]. In phase I/II studies of a recently deve-
loped rotavirus vaccine (116E) in India, breast milk was
withheld for half an hour before and after each vaccine
dose, and the seroconversion rate was almost 90% [14].
Other studies are also being conducted to assess the
modifying effect of breast milk on vaccine efficacy [15,16].
If these studies demonstrate an improvement in the im-
mune response by withholding breastfeeding around the
time of vaccination, this practice could be used to increase
the public health impact of rotavirus vaccination. How-
ever, little is known about mothers’ perceptions of
withholding breastfeeding and whether such an interven-
tion would be feasible and acceptable to mothers in
low-income settings.
The primary aim of the study was to assess the impact
of withholding breastfeeding compared to encouraging
breastfeeding on the immune response to Rotarix® in
infants. The results of the primary aim are not pre-
sented here. This paper describes the study methodology
and the mothers’ ability to adhere to the breastfeeding
recommendation as well as their perception of the
recommendation.Methods
Study setting
The trial was conducted in the urban resettlement neigh-
borhoods of Govindpuri-Tigri-Dakshipuri, Tuglakabad and
Sangam Vihar in South Delhi, India. These areas are typical
urban resettlement neighborhoods.
Randomization
The randomization list was generated by a statistician
independent of the study team. Subject ID allocation for
each participant was through serially numbered, opaque
sealed envelopes.
Sample size
The sample size was based on the primary aim of the
study. Assuming 60% seroconversion in the infants whose
mothers were encouraged to breastfed and 80% in the
group in whom breastfeeding was withheld, at 90% power
and alpha level of 5%, 200 infants were required in each
group. This sample also accounted for 30% dropouts and
10% who might be excluded from the analysis because of
high levels of antibodies at baseline.
Enrollment and intervention delivery
Participants were enrolled into the study from October
2012. Infants aged less than 7 weeks were identified
through a household survey. The families of infants aged
6 to 7 weeks were called to the study clinic for screening
and enrollment. Infants were enrolled if their parents
gave consent for participation, were aged 6 to 7 weeks,
had a weight-for-age Z score that was not ≤ −3 [17] and
were from a family with no plans to move out of the
study area in the next 4 months. Infants were excluded
if they were not breastfed, had already received a rota-
virus vaccination, had a chronic enteric disease and ill-
ness requiring hospital referral or causing diarrhea on
the day of enrollment or had a condition that the inves-
tigator judged to warrant exclusion, or if the mother or
infant had an immune deficiency disease.
During consent, families were informed that if they
agreed to take part in the study, their baby would be
randomly selected for either the withhold breastfeeding
or encourage breastfeeding group. All information was
provided in the local dialect. The verbatim information
in the informed consent form regarding allocation to
either group was:
You are being asked permission for your baby to be
screened for this study. This is to check if your baby is
healthy enough to receive the rotavirus vaccine and
the childhood vaccines. If your baby is assessed to be
well enough to receive the vaccine, your baby can take
part in this study. In case you agree to allow your
baby to participate, your baby will be randomly (like
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not be breastfed 30 minutes before and after receiving
the Rotarix®.
It was also explained that the purpose of the study was
to test: “The effect of not giving and giving breast milk
on the antibody response of the two doses of Rotarix®”.
The rationale for asking mothers to withhold or encou-
rage breastfeeding was: “Your baby’s participation in this
study may help in generating information about the
usefulness of giving or not giving breast milk before and
after the Rotarix® vaccine”.
After obtaining written informed consent, 400 eligible
mother–infant pairs were enrolled and randomized into
one of the two study groups.
Group 1: Mothers were advised to withhold
breastfeeding 30 min before and 30 min after each dose
of the vaccine.
Group 2: Mothers were encouraged to breastfeed
immediately before and after each dose of the vaccine.
The recommendation was given by a trained study
team nutritionist in both groups. The Group 1 mothers
were told: “You have been selected to be in the group
where breastfeeding needs to be withheld. Do not
breastfeed your child for half an hour before and after
receiving the rotavirus vaccine”. Group 2 mothers were
told: “You have been selected to be in the group where
you are encouraged to breastfeed your child in the half
an hour duration before and after receiving the rotavirus
vaccine”. At the study clinic there were two separate
designated areas for the two groups. Each area was super-
vised by clinical coordinators.
Mother–infant pairs were required to wait in the des-
ignated area as per their group allocation. All activities,
including specimen collection and administration of vac-
cines, were conducted in these areas. The team members
were present in the same area to observe the mother–
infant pairs during this time. After the 30 min of obser-
vation following Rotarix® administration, the infants were
administered the other childhood vaccines. In line with
usual practice, infants remained in the study clinic for
another 30 min after administration of the childhood
vaccines to allow observation, management and docu-
mentation of any immediate adverse events. In this
observation period, the women were not given any spe-
cific breastfeeding instructions, although breastfeeding
practices were recorded by the project team members.
Each enrolled infant was given two doses of the Rotarix®
vaccine along with a pentavalent vaccine (diphtheria,
pertussis, tetanus, hepatitis B and Haemophilus influenzae)
and an oral polio vaccine. The vaccines were administered
at the ages of 6 to 7 and 10 to 14 weeks, maintaining aminimum interval of 4 weeks between the two doses. The
third dose of the pentavalent vaccine was offered to all
infants when they came to the study clinic for the end of
study activities 4 weeks after the second dose of Rotarix®.
After enrollment, participants were contacted weekly
after each dose of Rotarix® to ascertain whether there were
any signs or symptoms of suspected intussusception or
whether they had suffered from an illness requiring hos-
pital referral or had been hospitalized. Severe adverse
events were reported to the Society for Applied Studies,
Ethics Review Committee (SAS-ERC). The follow-up of
the last child was completed in May 2013.
Data collection
Baseline information on maternal and infant characteris-
tics was collected at the time of enrollment. During the
observation period, details, such as the time the observa-
tion started and ended and the duration of any breastfeed-
ing, were documented in a form. After an infant received
the second dose of Rotarix®, its mother was asked a set of
structured questions about how she perceived the inter-
vention (the recommendation to withhold or encourage
breastfeeding). Mothers were also prompted to comment
on their answers.
Biological specimens from mothers and infants were
collected to assess immunogenicity. Baseline maternal
blood and breast milk specimens, and infant blood,
saliva and stool specimens were obtained. Before the
second dose of Rotarix®, maternal breast milk specimens
and infant saliva specimens were obtained. Four weeks
after the second dose of Rotarix®, blood, saliva and stool
specimens were collected from the infants.
Presentation of data
Descriptive measures of continuous variables are pre-
sented as means and standard deviations (SDs) for sym-
metrical data, and as medians and interquartile ranges
for skewed data. Descriptive measures of categorical data are
presented as frequencies and percentages. An independent-
samples t-test was used to explore the relationship
between continuous variables.
Ethical clearance
Ethical clearance was obtained from SAS-ERC (SAS ERC/
43/2012) and the South-East Regional Ethical Committee
of Norway (2012/193/REK). This study was conducted in
compliance with the protocol Good Clinical Practices and
other relevant regulatory guidelines.
Results
Of the 533 infants screened for eligibility, 400 were en-
rolled and randomized (Figure 1). Baseline infant charac-
teristics and socio-economic factors were comparable
between the two groups (Table 1). Nine subjects did not
Figure 1 Trial profile.
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participation and four moved out of the study area, leaving
391 subjects who received both doses of Rotarix® and
whose mothers completed the questionnaire on their
perception of the intervention.
The number of years in school varied greatly among
both mothers and fathers, from 0 to 17 and 0 to 19,
respectively. These distributions were similar in the two
study groups. Mothers in the group withholding breast-
feeding had a mean of 7.2 (SD, 4.8) years of education and
those in the group encouraged to breastfeed had a mean
of 7.0 (SD, 4.9) years. Similar figures were obtained for
men (8.9 (SD, 4.1) and 9.1 (SD, 4.4) years, respectively).
With the exception of one mother, all mothers who
were advised to withhold breastfeeding adhered fully to
this recommendation (Table 2). Similarly, all mothers
who were encouraged to breastfeed, except one, breast-
fed at least once (range one to four times) in each of
the periods before and after vaccine administration. One
woman did not breastfeed following the second doseof Rotarix®, but breastfed in the period before vaccine
administration.
The interval between the last breastfeed and the begin-
ning of the intervention period varied widely among
subjects, with maximum times of 491 and 388 min and
minimum times of 6 and 9 min for the first and second
doses, respectively. Mean intervals were significantly
longer for infants who were given supplementary nutri-
tion compared with those who were breastfed exclusively
(mean difference, 40 min; P = 0.002).
Almost 78% of the infants were not given any other
foods and fluids except breast milk; the mean number of
breastfeeds per day was ten times. It was found that 75%
of the infants in the group withholding breastfeeding
were being exclusively breastfed. Infants were not breast-
fed for about an average of 49 and 46 min after receiving
the first and second doses of Rotarix®, respectively.
Adherence to the breastfeeding recommendations was
high in both groups. Half of the mothers in each group
made additional comments on how they perceived the
Table 1 Baseline characteristics of participants in the study
Breastfeeding withheld (n = 200) Breastfeeding encouraged (n = 200)
Infant characteristics
Age at enrollment (days) (mean and SD) 48 (4.0) 49 (3.8)
Birth weight* (kg) (mean and SD) 2.80 (0.4) 2.84 (0.5)
Weight at screening (kg) (mean and SD) 4.41 (0.6) 4.43 (0.5)
Sex:
Boys 103 (51.5) 105 (52.5)
Girls 97 (48.5) 95 (47.5)
Exclusively breastfed 150 (75.0) 160 (80.0)
Socioeconomic characteristics
Home birth 61 (30.5) 52 (26.0)
Type of family:
Nuclear 112 (56.0) 115 (57.5)
Joint 88 (44.0) 85 (42.5)
Number of siblings (mean and SD) 0.95 (0.96) 1.1 (1.1)
Maternal age (years) (mean and SD) 24.4 (3.5) 24.8 (3.9)
Mother has not attended school 48 (24.0) 45 (22.5)
Father has not attended school 22 (11.0) 22 (11.0)
Family owns color television, cooler or scooter 182 (91.0) 179 (89.5)
Annual family income (rupees) (median and interquartile range) 84,000 (60,000, 120,000) 84,000 (72,000, 120,000)
All values are n (%) except when otherwise indicated. SD, standard deviation.
*Information on birth weight was available for 137 (68.5%) infants in the withholding breastfeeding group and 143 (71.5%) infants in the group encouraged
to breastfeed.
Table 2 Adherence to breastfeeding recommendations in the two groups
Breastfeeding withheld Breastfeeding encouraged
Dose 1 n = 200 n = 200
Time since last breastfeed (min) (median and IQR) 39 (33, 57) 100 (45, 152)
Pre-vaccine observation
Number breastfed during observation period 0 200
Total breastfeed duration (min) during observation period (mean and SD) − 11.8 (3.4)
Post-vaccine observation
Number breastfed during observation period 1 200
Total breastfeed duration (min) during observation period (mean and SD) 0.01 (0.1) 7.7 (3.6)
Dose 2 n = 195 n = 196
Time since last breastfeed (min) (median and IQR) 56 (34, 70) 68 (43, 105)
Pre-vaccine observation
Number breastfed during observation period 0 196
Total breastfeed duration (min) during observation period (mean and SD) − 10.7 (2.8)
Post-vaccine observation
Number breastfed during observation period 0 195
Total breastfeed duration (min) during observation period (mean and SD) − 6.5 (2.4)
All values are n (%) except when otherwise indicated. IQR, interquartile range; SD, standard deviation.
Rongsen-Chandola et al. Trials 2014, 15:256 Page 5 of 7
http://www.trialsjournal.com/content/15/1/256
Rongsen-Chandola et al. Trials 2014, 15:256 Page 6 of 7
http://www.trialsjournal.com/content/15/1/256intervention. The main emerging theme in both groups
was that the mothers found withholding breastfeeding
around the time of vaccination acceptable and feasible,
understanding that the vaccines were important and bene-
ficial for their child and by withholding breastfeeding they
could potentially improve the vaccine effect (Table 3).
Among mothers who were asked to withhold breast-
feeding for 30 min before and after vaccine administra-
tion, seven (4%) reported that this practice was difficult;
five found withholding breastfeeding stressful when their
infants cried, one found the interval to be too long and
one made no comment. Three of these seven infants were
breastfed exclusively. Only one mother reported that with-
holding breastfeeding would be a reason for not giving the
rotavirus vaccine to her infant, commenting that the
duration of the non-breastfeeding period was too long.
All mothers withholding breastfeeding reported that
they would adhere to this practice if asked to do so by
health-care professionals. Thirteen of them said that they
would do so since they understood the importance of
vaccination. Two mothers said that they did the same when
the health workers in the immunization center asked
them to do so during oral polio vaccine administration.
Of the mothers who did not find withholding breast-
feeding difficult, nine commented that their baby was
calm and slept during the observation period, eight com-
mented that the observation period was not too long
and five reiterated that they did not find it difficult to
withhold breastfeeding.
Discussion
This study assessed the feasibility of asking mothers to
withhold breastfeeding. Mothers did not have any diffi-
culty in complying with this request. The fact that al-
most all mothers adhered to the recommendations is
encouraging and this practice can potentially be adopted
into policy. It was also observed that the recommenda-
tion appeared to be acceptable to mothers as they
perceived it to be beneficial for their children.
The time of 30 min was chosen since this was assumed
to be a reasonable time limit for withholding breastfeeding.Table 3 Mothers’ perception of breastfeeding recommendatio
Breastfeeding withheld (n = 195)
Found it difficult to withhold breastfeeding for 30 min before and after Rota
She would withhold breastfeeding around time of vaccination if health-care
Withholding breastfeeding would be a reason not to give rotavirus vaccine t
Breastfeeding encouraged (n = 196)
Found it difficult to breastfeed for 30 min before and after Rotarix®
She would breastfeed around time of vaccination if health-care provider aske
Breastfeeding would be a reason not to give rotavirus vaccine to her babyStudies show that the half gastric emptying time varies
between 47 and 61 min [18-20]. Withholding breast-
feeding for an hour before and after may not have been
feasible in this setting. Many infants would likely have been
offered supplementary food or water and the intervention
could inadvertently have interfered with the World Health
Organization’s recommendation of exclusive breastfeeding
for the first 6 months of life. The 30 min time interval was
used in the rotavirus vaccine 116E trials in Delhi [14],
which demonstrated good immunogenicity for the vaccine.
At least two other studies are underway to assess the
importance of withholding breast milk to improve the im-
munogenicity of oral vaccines [15,16]. Advising mothers to
withhold breast milk around the time of vaccination may
be contemplated if there is clear benefit. It is essential that
children get the maximum effect from their life-saving vac-
cines and at the same time it is essential to ensure that the
benefits of breastfeeding are not undermined. Clear mes-
sages should be developed and tested further before being
used in a program setting. It is important that the mothers
understand that withholding breastfeeding around the time
of vaccination may be required not because there are
harmful substances in breast milk but because the benefi-
cial substances may work against the effect of the vaccine.
This study was conducted with a limited population
and the investigators did not measure the mothers’ un-
derstanding of the breastfeeding recommendations. It is
likely that the high compliance seen in this study is an
artifact of the study setting for several reasons. Firstly,
the recommendations were given by trained study team
members with a background in nutrition and skilled in
delivering the message. In this setting, it is well known
that mothers are more likely to listen to health workers
whom they perceive to be of a higher position and quali-
fication: advice given by physicians or nutritionists is
more likely to be adhered to. Secondly, the study team
members who gave the recommendations also observed
the mothers and were present in the same area as the
mother–infant pairs. Thirdly, it is possible that the
group of mothers who consented to participate in this
study were inherent compliers. It is also likely that thens
Yes No
rix® 7 188
provider asked her 195 0
o her baby 1 194
1 195
d her 196 0
2 194
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different in other settings.
The study was conducted in urban resettlement neigh-
borhoods of South Delhi. Though the participants in this
study represent an important group, the generalizability of
the study is limited since all the participants were from
one area of Delhi. Nevertheless, reporting good quality
data generated from smaller studies like this is important
before considering larger trials in the population.
Conclusions
In conclusion, mothers in this setting complied with the
recommendations given by the study team to withhold
breastfeeding or breastfeed half an hour before and
after vaccination. It is likely that the mothers perceived
the recommendation to have potential benefits to the
health of their infants, therefore resulting in the high
compliance.
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